These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
484 related articles for article (PubMed ID: 19810140)
1. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C J BUON; 2009; 14(3):463-72. PubMed ID: 19810140 [TBL] [Abstract][Full Text] [Related]
2. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer]. Zissimopoulos A; Petrakis G; Stellos K; Baziotis N Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400 [TBL] [Abstract][Full Text] [Related]
3. [Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma]. Zissimopoulos A; Stellos C; Petrakis G; Baziotis N Hell J Nucl Med; 2004; 7(3):162-7. PubMed ID: 15841291 [TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Tähtelä R; Thölix E Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558 [TBL] [Abstract][Full Text] [Related]
5. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. Noguchi M; Noda S J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307 [TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP]. Kobayashi Y; Ochi M; Tokue A Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802 [TBL] [Abstract][Full Text] [Related]
7. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545 [TBL] [Abstract][Full Text] [Related]
8. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881 [TBL] [Abstract][Full Text] [Related]
9. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770 [TBL] [Abstract][Full Text] [Related]
10. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583 [TBL] [Abstract][Full Text] [Related]
11. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Ebert W; Muley T; Herb KP; Schmidt-Gayk H Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610 [TBL] [Abstract][Full Text] [Related]
12. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer. Keskikuru R; Kataja V; Kosma VM; Eskelinen M; Uusitupa M; Johansson R; Risteli L; Risteli J; Jukkola A Anticancer Res; 1999; 19(5C):4481-4. PubMed ID: 10650796 [TBL] [Abstract][Full Text] [Related]
13. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients]. Kobayashi Y; Tokue A Nihon Rinsho; 1998 Aug; 56(8):2072-6. PubMed ID: 9750510 [TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer. Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M Respirology; 2005 Jun; 10(3):300-4. PubMed ID: 15955141 [TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Akimoto S; Akakura K; Shimazaki J Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556 [TBL] [Abstract][Full Text] [Related]
16. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381 [TBL] [Abstract][Full Text] [Related]
17. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Koizumi M; Takahashi S; Ogata E Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607 [TBL] [Abstract][Full Text] [Related]
18. Type I collagen metabolites as tumor markers in patients with lung carcinoma. Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235 [TBL] [Abstract][Full Text] [Related]
19. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer. Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361 [TBL] [Abstract][Full Text] [Related]
20. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases]. Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]